Published on 22/12/2025
Common Mistakes in Trial Results Reporting and How to Fix Them
Introduction: Importance of Accurate Results Reporting
Accurate reporting of clinical trial results on public registries such as ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) is a regulatory and ethical obligation. However, due to differences in data structure, formatting requirements, and limited internal QC, sponsors often make avoidable mistakes. These can lead to public queries, regulatory penalties, or inspection findings.
This article outlines the most common reporting errors and provides practical guidance on how to detect, correct, and prevent them using compliance-driven processes and quality checks.
Error 1: Participant Flow Inconsistencies
One of the most common issues is mismatch in the number of participants reported in the CSR vs. the registry’s participant flow section. Often, dropout counts, group allocation numbers, or “not treated” status are either omitted or misclassified.
Example: A sponsor reports 300 participants enrolled in the CSR, but only 285 are listed under “Started” in the ClinicalTrials.gov table, triggering a discrepancy flag.
Fix Strategy: Maintain a mapping file between raw dataset, CSR participant flow section, and registry summary. Ensure consistent terminology across all outputs. Use auto-validation tools within
Error 2: Baseline Data Incompleteness
Missing demographic or baseline characteristics can undermine the interpretability of outcomes. For example, failing to report gender breakdown or mean age per arm is a common error in CTIS uploads.
Corrective Action: Create a results summary template that includes mandatory fields as per registry specifications. Implement baseline checks within your medical writing review SOPs to ensure completeness prior to upload.
Error 3: Outcome Measure Discrepancies
This occurs when primary or secondary outcome measures listed in the registry do not match the final values presented in the CSR or are inconsistent across platforms. Even small shifts in timepoints, units, or populations analyzed can raise compliance issues.
Preventive Measure: Lock the protocol outcome definitions and registry fields early. Train teams on consistent use of endpoint terminology. Use the same SAS output table structure for both CSR and registry to reduce discrepancies.
Example Mapping Table
| Registry Outcome | CSR Table | Common Error | Fix |
|---|---|---|---|
| Change in HbA1c from baseline | Table 11.2.2.3 | Different units (mmol/mol vs %) | Align unit conventions in protocol and registry |
| Proportion achieving viral suppression | Table 12.3.1 | Different denominator reported | Use same analysis population definitions |
Error 4: Adverse Events Underreporting
Adverse events (AEs) are frequently misreported or incompletely disclosed due to complexity in coding and threshold application. CT.gov requires separate reporting of serious and non-serious AEs, both overall and per arm, with incidence thresholds. Failure to meet these standards can trigger public flags.
Correction Plan: Use MedDRA-based listings and confirm AE frequencies meet the reporting threshold (e.g., ≥5%). Validate that the CSR AE summary matches registry counts. Use PRS preview to verify expected tabular structure.
Error 5: Redaction and Data Privacy Violations
When posting lay summaries or results in the public domain, companies often neglect to remove sensitive personal data. Redaction errors can include naming trial sites, exposing investigator initials, or disclosing rare AE narratives that could lead to patient reidentification.
Compliance Action: Implement a two-level redaction review (medical and legal) before publishing. Use standard templates and refer to the EMA’s redaction guidance under Policy 0070. Consider using AI-powered redaction tools integrated into your disclosure platform.
CAPA Strategy for Disclosure Errors
When a significant registry error is discovered (e.g., underreporting of deaths, incorrect outcome values), implement a formal Corrective and Preventive Action (CAPA) procedure. A standard CAPA workflow involves:
- Documenting the nature of the error and when it was identified.
- Analyzing the root cause (e.g., version mismatch, training gap, miscommunication).
- Updating the result fields with correct values.
- Retraining involved teams on registry specifications.
- Monitoring future uploads through QC checklists.
For examples of SOPs and CAPA templates, refer to PharmaSOP.in.
QA and Audit-Ready Processes
To maintain inspection readiness, QA teams should perform periodic audits of posted results. The checklist may include:
- Review of posting deadlines and actual upload dates
- Consistency check between CSR, registry, and protocol-defined endpoints
- Verification of PRS or CTIS validation success messages
- Archival of screenshots and system logs for audit trail
Additionally, establishing disclosure quality metrics—such as error rate per upload or cycle time from CSR finalization to public posting—can support continuous improvement initiatives.
Regulatory Trends and Inspection Insights
Agencies like the FDA and EMA are increasingly focusing on result disclosure accuracy during inspections. FDA Form 483 observations have cited inconsistencies between protocol-specified outcomes and posted summaries. The EMA also requires alignment of CTIS results with Module 5 documents of the Marketing Authorisation Application (MAA).
According to FDA guidance on ClinicalTrials.gov reporting, noncompliance can lead to notices of non-submission and potential civil monetary penalties. Early planning, clear roles, and checklists are essential to avoid such findings.
Conclusion
Inaccurate results reporting can have far-reaching implications—from regulatory penalties to loss of public trust. Understanding common mistakes such as data mismatches, baseline gaps, AE underreporting, and redaction errors is the first step. The second is establishing robust SOPs, QC workflows, and training modules for registry submissions.
By treating results disclosure as an integrated part of CSR and regulatory operations—not a post-hoc administrative task—sponsors can ensure transparency, compliance, and audit readiness. Tools like checklist-driven disclosure portals, redaction workflows, and cross-functional team training will form the cornerstone of future-ready disclosure strategy.
For further guidance, explore tools and regulatory harmonization documents at EMA or visit ClinicalStudies.in for real-world examples.